Related Experiment Videos
Human fascioliasis: cure by mebendazole? A case report
Gastroenterologie Clinique Et Biologique
|June 1, 1986
Summary
High-dose mebendazole successfully treated invasive human Fasciola hepatica infection. This approach normalized eosinophil counts, liver enzymes, and serology, eradicating liver flukes.
Area of Science:
- Parasitology
- Hepatology
- Pharmacology
Background:
- Human fascioliasis is a liver fluke infection caused by Fasciola hepatica.
- Invasive infections can lead to significant liver damage and require effective treatment.
- Current treatment options for severe fascioliasis have limitations.
Observation:
- A case of invasive human Fasciola hepatica infection was observed.
- The patient presented with eosinophilia, abnormal liver enzymes, and liver necrosis.
- Standard treatments were not detailed in this specific case report.
Findings:
- High-dose mebendazole (4 g/day for 3 weeks) was administered.
- This treatment led to prompt and sustained normalization of eosinophil counts.
- Liver enzymes normalized, serological tests improved, and liver necrosis resolved, indicating fluke eradication.
Implications:
- Mebendazole, at high doses, shows potential as a novel treatment for invasive human fascioliasis.
- This case suggests a new therapeutic avenue for liver fluke infections.
- Further clinical studies are necessary to confirm the efficacy and safety of mebendazole for fascioliasis.